JT ponders dalcetrapib's future in wake of Roche no-go decision
This article was originally published in Scrip
Executive Summary
Following partner Roche's decision to discontinue the development of dalcetrapib, the molecule's originator Japan Tobacco is now assessing its future strategy for the cholesterol-modifying product.